scholarly journals Topical Tofacitinib: A Janus Kinase Inhibitor for the Treatment of Vitiligo in an Adolescent Patient

2021 ◽  
pp. 190-194
Author(s):  
Sineida Berbert Ferreira ◽  
Rachel Berbert Ferreira ◽  
Afonso Cesar Neves Neto ◽  
Silvana Martins Caparroz Assef ◽  
Morton Scheinberg
Keyword(s):  
Case Report ◽  
Skin Disease ◽  
Kinase Inhibitor ◽  
Effective Therapy ◽  
Janus Kinase ◽  
Jak Inhibitor ◽  
Adolescent Patient ◽  
Jak Inhibitors ◽  
Janus Kinase Inhibitor ◽  
History Of

Vitiligo is an autoimmune skin disease presenting with areas of depigmentation. Recent reports suggest that Janus kinase (JAK) inhibitors may be an effective therapy. In this case report, we show our experience with an adolescent patient with a long history of generalized and refractory vitiligo, for which treatment with topical tofacitinib, a JAK inhibitor, associated with phototherapy for 9 months, resulted in near complete repigmentation.

scholarly journals Chronic Myeloid Leukemia in a Patient Receiving Tofacitinib: A Case Report and Literature Review

2019 ◽  
Vol 2019 ◽  
pp. 1-4
Author(s):  
Georgio Medawar ◽  
Joseph Chahrouri ◽  
Rabih Said
Keyword(s):  
Rheumatoid Arthritis ◽  
Case Report ◽  
Myeloid Leukemia ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Myelogenous Leukemia ◽  
Janus Kinase Inhibitor ◽  
Case Presentation ◽  
Rheumatologic Diseases ◽  
Refractory Rheumatoid Arthritis

Background. Tofacitinib is a new oral Janus kinase inhibitor that has shown promising clinical benefit in various rheumatologic diseases. However, many concerns related to the development of malignancies have been reported with its use. Case Presentation. A 43-year-old female patient received tofacitinib for refractory rheumatoid arthritis (RA). Two years after 5 mg bid daily dosing, the patient developed chronic myelogenous leukemia (CML), for which she received imatinib and tofacitinib was discontinued. She then remained in remission for rheumatoid arthritis and within the expected milestone outcome for her CML. Conclusion. This is the first reported case of CML after the use of tofacitinib. This event is of particular interest knowing the possible benefits tofacitinib carries in the treatment of CML demonstrated in a few studies.

scholarly journals Tofacitinib as an Adjunct Immunomodulator for Treatment of a Patient with Severe COVID-19: A Case Report

2021 ◽  
Vol 59 (238) ◽  
Author(s):  
Gentle Sunder Shrestha ◽  
Bidesh Bista ◽  
Ashesh Dhungana ◽  
Nimesh Poudel ◽  
Shraddha Bhattarai ◽  
...  
Keyword(s):  
Case Report ◽  
Kinase Inhibitor ◽  
Significant Proportion ◽  
Janus Kinase ◽  
Inflammatory Biomarkers ◽  
Janus Kinase Inhibitor ◽  
Improve Outcome ◽  
Respiratory Status ◽  
Progressive Respiratory Failure ◽  
High Level

Severe coronavirus disease 2019 can be associated with progressive respiratory failure. In addition to respiratory support and other supportive care, use of corticosteroids has shown to improve outcome. Despite the use of steroids, a significant proportion of patients progressively worsen. Adjunct immunomodulators have been studied in addition to steroids in these patients. Here we present a successful use of tofacitinib, a Janus Kinase inhibitor, in conjunction with dexamethasone for a patient with rapid worsening of respiratory status and with high level of serum inflammatory biomarkers.

scholarly journals Extraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis

2021 ◽  
Vol 14 ◽  
pp. 175628482110057
Author(s):  
David T. Rubin ◽  
Walter Reinisch ◽  
Thomas Greuter ◽  
Paulo G. Kotze ◽  
Marcia Pinheiro ◽  
...  
Keyword(s):  
Ulcerative Colitis ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Extraintestinal Manifestations ◽  
Peripheral Arthritis ◽  
Janus Kinase Inhibitor ◽  
Clinical Program ◽  
History Of ◽  
The Impact ◽  
Maintenance Study

Introduction: Extraintestinal manifestations (EIMs) in patients with ulcerative colitis (UC) are common. Tofacitinib is an oral, small molecule Janus kinase inhibitor for the treatment of UC. We evaluated the efficacy of tofacitinib in patients with EIMs, and the impact of tofacitinib on EIMs in patients with UC in the OCTAVE clinical program. Methods: Data from two 8-week induction studies (OCTAVE Induction 1 and 2) and a 52-week maintenance study (OCTAVE Sustain) were analyzed. The effect of tofacitinib on efficacy outcomes stratified by EIM status, proportion of predefined prior and active EIMs at baseline, and change from baseline in EIMs were determined at the end of the treatment period (weeks 8 or 52), or at early termination. Results: At baseline of OCTAVE Induction 1 and 2, and OCTAVE Sustain, 27.0% and 9.0% of patients had a history of EIMs (prior or active), respectively. Patients treated with tofacitinib 10 mg twice daily (BID) achieved remission and had endoscopic improvement in all studies, irrespective of any history of EIMs. A greater proportion of patients had active peripheral arthritis at baseline of OCTAVE Induction 1 and 2 versus OCTAVE Sustain. In OCTAVE Induction 1 and 2, similar proportions of tofacitinib and placebo-treated patients with active peripheral arthritis experienced either no change (81.3% and 85.7%, respectively) or an improvement (15.6% and 14.3%, respectively). By week 52 of OCTAVE Sustain, improvements in active peripheral arthritis were only observed in tofacitinib-treated patients (16.7% and 33.3% with tofacitinib 5 and 10 mg BID, respectively). Conclusion: Any history of EIMs did not influence the efficacy of tofacitinib 10 mg BID for induction or maintenance of UC. The most common active EIM was peripheral arthritis, for which many patients in OCTAVE Induction 1 and 2, and OCTAVE Sustain, reported improvement or no change from baseline with tofacitinib treatment. Clinicaltrials.gov:NCT01465763 ; NCT01458951; NCT01458574

scholarly journals Accumulation of JAK activation loop phosphorylation is linked to type I JAK inhibitor withdrawal syndrome in myelofibrosis

2018 ◽  
Vol 4 (11) ◽  
pp. eaat3834 ◽  
Author(s):  
Denis Tvorogov ◽  
Daniel Thomas ◽  
Nicholas P. D. Liau ◽  
Mara Dottore ◽  
Emma F. Barry ◽  
...  
Keyword(s):  
Drug Withdrawal ◽  
Kinase Inhibitor ◽  
Janus Kinase ◽  
Activation Loop ◽  
Type I ◽  
Type Ii ◽  
Jak Inhibitor ◽  
Janus Kinase Inhibitor ◽  
Life Threatening ◽  
Dose Dependent

Treatment of patients with myelofibrosis with the type I JAK (Janus kinase) inhibitor ruxolitinib paradoxically induces JAK2 activation loop phosphorylation and is associated with a life-threatening cytokine-rebound syndrome if rapidly withdrawn. We developed a time-dependent assay to mimic ruxolitinib withdrawal in primary JAK2V617Fand CALR mutant myelofibrosis patient samples and observed notable activation of spontaneous STAT signaling in JAK2V617Fsamples after drug washout. Accumulation of ruxolitinib-induced JAK2 phosphorylation was dose dependent and correlated with rebound signaling and the presence of a JAK2V617Fmutation. Ruxolitinib prevented dephosphorylation of a cryptic site involving Tyr1007/1008in JAK2 blocking ubiquitination and degradation. In contrast, a type II JAK inhibitor, CHZ868, did not induce JAK2 phosphorylation, was not associated with withdrawal signaling, and was superior in the eradication of flow-purified JAK2V617Fmutant CD34+progenitors after drug washout. Type I inhibitor–induced loop phosphorylation may act as a pathogenic signaling node released upon drug withdrawal, especially in JAK2V617Fpatients.

scholarly journals Cementless bipolar hemiarthroplasty in a patient with PMF: a case report

2019 ◽  
Vol 2019 (11) ◽  
Author(s):  
Abdullah A Alturki ◽  
Nayf A Alshammari ◽  
Firas M Alsebayel ◽  
Ali A Alhandi
Keyword(s):  
Kinase Inhibitor ◽  
Myeloproliferative Neoplasms ◽  
Primary Myelofibrosis ◽  
Janus Kinase ◽  
Bipolar Hemiarthroplasty ◽  
Myeloproliferative Disease ◽  
Neck Of Femur ◽  
Janus Kinase Inhibitor ◽  
History Of ◽  
Neck Of Femur Fracture

Abstract Myelofibrosis is a myeloproliferative disease that falls under a group of bone marrow malignancies known as myeloproliferative neoplasms. It manifests with splenomegaly, anemia, leukocytosis and, less commonly, bone pain. Ruxolitinib, Janus kinase inhibitor, has been shown to increase survival, to improve symptoms and has the potential to decrease osteosclerotic changes. Herein, we present a case of primary myelofibrosis (PMF) in a 60-year-old female who presented with 8-month history of progressive left hip pain and later was diagnosed with pathological neck of femur fracture that was treated with cementless hemiarthroplasty. In conclusion, the use of cementless implants in hip arthroplasty in the presence of PMF has shown to be an effective and safe choice.

Sign in / Sign up

Export Citation Format

Share Document